As­traZeneca ex­pands stake in cell and gene ther­a­py part­ner Cel­lec­tis

UK phar­ma gi­ant As­traZeneca on Mon­day un­veiled an­oth­er $140 mil­lion eq­ui­ty in­vest­ment in cell and gene ther­a­py part­ner Cel­lec­tis.

As­traZeneca now owns 44% of Cel­lec­tis’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER